Literature DB >> 18421457

Correlation of [18F]FMISO autoradiography and pimonidazole [corrected] immunohistochemistry in human head and neck carcinoma xenografts.

Esther G C Troost1, Peter Laverman, Mariëlle E P Philippens, Jasper Lok, Albert J van der Kogel, Wim J G Oyen, Otto C Boerman, Johannes H A M Kaanders, Johan Bussink.   

Abstract

PURPOSE: Tumour cell hypoxia is a common feature in solid tumours adversely affecting radiosensitivity and chemosensitivity in head and neck squamous cell carcinomas. Positron emission tomography (PET) using the tracer [(18)F]fluoromisonidazole ([(18)F]FMISO) is most frequently used for non-invasive evaluation of hypoxia in human tumours. A series of ten human head and neck xenograft tumour lines was used to validate [(18)F]FMISO as hypoxia marker at the microregional level.
METHODS: Autoradiography after injection of [(18)F]FMISO was compared with immunohistochemical staining for the hypoxic cell marker pimonidazole in the same tumour sections of ten different human head and neck xenograft tumour lines. The methods were compared: first, qualitatively considering the microarchitecture; second, by obtaining a pixel-by-pixel correlation of both markers at the microregional level; third, by measuring the signal intensity of both images; and fourth, by calculating the hypoxic fractions by pimonidazole labelling.
RESULTS: The pattern of [(18)F]FMISO signal was dependent on the distribution of hypoxia at the microregional level. The comparison of [(18)F]FMISO autoradiography and pimonidazole immunohistochemistry by pixel-by-pixel analysis revealed moderate correlations. In five tumour lines, a significant correlation between the mean [(18)F]FMISO and pimonidazole signal intensity was found (range, r(2)=0.91 to r(2)=0.99). Comparison of the tumour lines with respect to the microregional distribution pattern of hypoxia revealed that the correlation between the mean signal intensities strongly depended on the microarchitecture. Overall, a weak but significant correlation between hypoxic fractions based on pimonidazole labeling and the mean [(18)F]FMISO signal intensity was observed (r(2)=0.18, p=0.02). For the three tumour models with a ribbon-like microregional distribution pattern of hypoxia, the correlation between the hypoxic fraction and the mean [(18)F]FMISO signal intensity was much stronger and more significant (r(2)=0.73, p<0.001) than for the tumours with a more homogenous, patchy, microregional distribution pattern of hypoxia.
CONCLUSION: Different patterns of [(18)F]FMISO accumulation dependent on the underlying microregional distribution of hypoxia were found in ten head and neck xenograft tumours. A weak albeit significant correlation was found between the mean [(18)F]FMISO signal intensity and the hypoxic fraction of the tumours. In larger clinical tumours, [(18)F]FMISO-PET provides information on the tumour oxygenation status on a global level, facilitating dose painting in radiation treatment planning. However, caution must be taken when studying small tumour subvolumes as accumulation of the tracer depends on the presence of hypoxia and on the tumour microarchitecture.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18421457     DOI: 10.1007/s00259-008-0772-7

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  33 in total

1.  Imaging of hypoxia in human tumors with [F-18]fluoromisonidazole.

Authors:  W J Koh; J S Rasey; M L Evans; J R Grierson; T K Lewellen; M M Graham; K A Krohn; T W Griffin
Journal:  Int J Radiat Oncol Biol Phys       Date:  1992       Impact factor: 7.038

2.  Double-tracer autoradiography with Cu-ATSM/FDG and immunohistochemical interpretation in four different mouse implanted tumor models.

Authors:  Takeshi Tanaka; Takako Furukawa; Shigeharu Fujieda; Shingo Kasamatsu; Yoshiharu Yonekura; Yasuhisa Fujibayashi
Journal:  Nucl Med Biol       Date:  2006-07-18       Impact factor: 2.408

3.  Hypoxia and vascular endothelial growth factor expression in human squamous cell carcinomas using pimonidazole as a hypoxia marker.

Authors:  J A Raleigh; D P Calkins-Adams; L H Rinker; C A Ballenger; M C Weissler; W C Fowler; D B Novotny; M A Varia
Journal:  Cancer Res       Date:  1998-09-01       Impact factor: 12.701

4.  A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85.

Authors:  J Overgaard; H S Hansen; M Overgaard; L Bastholt; A Berthelsen; L Specht; B Lindeløv; K Jørgensen
Journal:  Radiother Oncol       Date:  1998-02       Impact factor: 6.280

5.  A confirmatory prognostic study on oxygenation status and loco-regional control in advanced head and neck squamous cell carcinoma treated by radiation therapy.

Authors:  M Nordsmark; J Overgaard
Journal:  Radiother Oncol       Date:  2000-10       Impact factor: 6.280

6.  Prognostic impact of hypoxia imaging with 18F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy.

Authors:  Susanne-Martina Eschmann; Frank Paulsen; Matthias Reimold; Helmut Dittmann; Stefan Welz; Gerald Reischl; Hans-Juergen Machulla; Roland Bares
Journal:  J Nucl Med       Date:  2005-02       Impact factor: 10.057

7.  Carbonic anhydrase IX expression, hypoxia, and prognosis in patients with uterine cervical carcinomas.

Authors:  David Hedley; Melania Pintilie; Jennifer Woo; Andrew Morrison; Diana Birle; Anthony Fyles; Michael Milosevic; Richard Hill
Journal:  Clin Cancer Res       Date:  2003-11-15       Impact factor: 12.531

8.  Measurements of hypoxia using pimonidazole and polarographic oxygen-sensitive electrodes in human cervix carcinomas.

Authors:  Marianne Nordsmark; Juliette Loncaster; Christina Aquino-Parsons; Shu Chuan Chou; Morten Ladekarl; Hanne Havsteen; Jacob C Lindegaard; Susan E Davidson; Mahesh Varia; Catharine West; Robin Hunter; Jens Overgaard; James A Raleigh
Journal:  Radiother Oncol       Date:  2003-04       Impact factor: 6.280

9.  Measurements of hypoxia ([(18)F]-FMISO, [(18)F]-EF5) with positron emission tomography (PET) and perfusion using PET ([(15)O]-H(2)O) and power Doppler ultrasonography in feline fibrosarcomas*.

Authors:  K Allemann; M T Wyss; M Wergin; S Ohlerth; C Rohrer-Bley; S M Evans; A P Schubiger; S M Ametamey; B Kaser-Hotz
Journal:  Vet Comp Oncol       Date:  2005-12       Impact factor: 2.613

10.  Vascular architecture, hypoxia, and proliferation in first-generation xenografts of human head-and-neck squamous cell carcinomas.

Authors:  Anna S E Ljungkvist; Johan Bussink; Paulus F J W Rijken; Johannes H A M Kaanders; Albert J van der Kogel; Juliana Denekamp
Journal:  Int J Radiat Oncol Biol Phys       Date:  2002-09-01       Impact factor: 7.038

View more
  27 in total

Review 1.  Highlights from 2017: impactful topics published in the Annals of Nuclear Medicine.

Authors:  Andrea Farolfi; Pietro Ghedini; Stefano Fanti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-09-28       Impact factor: 9.236

2.  A Novel PET Probe "[18F]DiFA" Accumulates in Hypoxic Region via Glutathione Conjugation Following Reductive Metabolism.

Authors:  Yoichi Shimizu; Songji Zhao; Hironobu Yasui; Ken-Ichi Nishijima; Hiroki Matsumoto; Tohru Shiga; Nagara Tamaki; Mikako Ogawa; Yuji Kuge
Journal:  Mol Imaging Biol       Date:  2019-02       Impact factor: 3.488

3.  Tumour microenvironment heterogeneity affects the perceived spatial concordance between the intratumoural patterns of cell proliferation and 18F-fluorothymidine uptake.

Authors:  Marian Axente; Jun He; Christopher P Bass; Jerry I Hirsch; Gobalakrishnan Sundaresan; Jeffrey Williamson; Jamal Zweit; Andrei Pugachev
Journal:  Radiother Oncol       Date:  2012-03-21       Impact factor: 6.280

Review 4.  Molecular imaging of tumor hypoxia with positron emission tomography.

Authors:  Olivia J Kelada; David J Carlson
Journal:  Radiat Res       Date:  2014-03-27       Impact factor: 2.841

Review 5.  The promise and pitfalls of positron emission tomography and single-photon emission computed tomography molecular imaging-guided radiation therapy.

Authors:  Richard L Wahl; Joseph M Herman; Eric Ford
Journal:  Semin Radiat Oncol       Date:  2011-04       Impact factor: 5.934

Review 6.  PET radiopharmaceuticals for imaging of tumor hypoxia: a review of the evidence.

Authors:  Egesta Lopci; Ilaria Grassi; Arturo Chiti; Cristina Nanni; Gianfranco Cicoria; Luca Toschi; Cristina Fonti; Filippo Lodi; Sandro Mattioli; Stefano Fanti
Journal:  Am J Nucl Med Mol Imaging       Date:  2014-06-07

Review 7.  Positron emission tomography to assess hypoxia and perfusion in lung cancer.

Authors:  Eline E Verwer; Ronald Boellaard; Astrid Am van der Veldt
Journal:  World J Clin Oncol       Date:  2014-12-10

8.  (18)F-misonidazole PET imaging of hypoxia in micrometastases and macroscopic xenografts of human non-small cell lung cancer: a correlation with autoradiography and histological findings.

Authors:  Tao Huang; A Cahid Civelek; Huaiyu Zheng; Chin K Ng; Xiaoxian Duan; Junling Li; Gregory C Postel; Baozhong Shen; Xiao-Feng Li
Journal:  Am J Nucl Med Mol Imaging       Date:  2013-03-08

Review 9.  Tumor hypoxia: a new PET imaging biomarker in clinical oncology.

Authors:  Nagara Tamaki; Kenji Hirata
Journal:  Int J Clin Oncol       Date:  2015-11-14       Impact factor: 3.402

Review 10.  Molecular imaging of hypoxia with radiolabelled agents.

Authors:  Gilles Mees; Rudi Dierckx; Christel Vangestel; Christophe Van de Wiele
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-06-30       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.